Global Central Nervous System Therapeutics Market: Industry Analysis and Forecast (2020-2026) By Disease Type, Drug Class, End-Users and Region

Global Central Nervous System Therapeutics Market size is expected to reach US$ 139.50 Bn. by year 2026 at a CAGR of 9.4% during the forecast period.

Global Central Nervous System Therapeutics Market Overview:

The central nervous system (CNS) is the body's command center, controlling cognition, movement, sensation, and emotion. The central nervous system is made up of a collection of neurological disorders that affect the structure or function of the brain and spinal cord (CNS).

Global Central Nervous System Therapeutics Market Dynamics:

Rising prevalence of neurological diseases is expected to drive the market growth.

Alzheimer disease is responsible for around 1.2 million adult-onset brain problems, according to the World Health Organization (WHO). In addition, nearly 60,000 people in the United States have been diagnosed with Parkinson's disease. During the forecast period, the rising frequency of neurological illnesses is likely to promote the adoption of improved central nervous system treatment options. All of the major pharmaceutical firms have invested in and developed innovative medicines for the treatment of CNS illnesses due to the huge unmet medical demand. Furthermore, an increase in generics is predicted to drive CNS medication penetration into low- and middle-income countries, making them more inexpensive. Increasing awareness efforts may also result in medications being more readily available. Furthermore, the global central nervous system therapy market is likely to benefit from the availability of modern healthcare facilities in the future years. For example, the FDA approved two new generic versions of Copaxone in 2018, which is projected to strengthen competitive competition in the central nervous system therapeutic market. Regulatory guidelines and crucial clinical trials are promoting the introduction of new central nervous system therapeutics to the market. The efficacy, dose, formulation, and side effects of these medications are all closely evaluated. The market is expected to grow throughout the projected period due to the fast-growing elderly population, which is leading to an increase in the number of neurological disease cases. The report has profiled fifteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Central Nervous System Therapeutics Market Segment Analysis:

The Global Central Nervous System Therapeutics Market is segmented on the basis of Disease Type, Drug Class and End-Users.

Based on Disease Type, the Neurodegenerative diseases segment is expected to dominate the global market during forecast years. According to the WHO, dementia affects 50 million people worldwide, with approximately 60% of them residing in low- and middle-income countries. It predicts that by 2030, the number will have risen to 82 million. According to the Parkinson's Foundation, 2.8 million people worldwide have multiple sclerosis and 10 million have Parkinson's disease. Over the projection period, the degenerative disease segment will account for a significant portion of the market. Nerve cells in the brain and peripheral nervous systems lose their function and perish, resulting in this disease. The rising prevalence of Alzheimer's disease, Parkinson's disease, and multiple sclerosis is responsible for the majority of it. Furthermore, the segment is projected to be driven by strong pipeline candidates for the treatment of neurological illness. For example, there are more than 130 medication candidates in development for the treatment of Alzheimer's disease around the world. Global Central Nervous System Therapeutics Market To know about the Research Methodology :- Request Free Sample Report

Global Central Nervous System Therapeutics Market Regional Insights:

Global Central Nervous System Therapeutics Market 1

North America held the dominant market share in 2020.

Over the forecast period, North America is likely to dominate the CNS therapies market. According to GBD 2019, neurological illnesses were the third leading cause of death in Canada and the fourth leading cause of death in the United States in 2019. According to the Alzheimer's Disease Facts and Figures Report, 5.8 million Americans had dementia in 2019, with 5.6 million of them being 65 or older. The existence of prominent companies in the region, as well as important firms' increasing initiatives to discover novel medicines for various central nervous system illnesses, are projected to boost total market share. Furthermore, the growing prevalence of mental health and neurodegenerative disorders such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, and epilepsy is driving demand for central nervous system therapies in North America. Pharmaceutical companies' awareness campaigns on CNS disease diagnosis and treatment, as well as better payment regulations for CNS illness treatment, have increased the region's treatment rate. The US Congress has allocated approximately USD 10 million to multiple sclerosis research, with the possibility of an additional USD 20 million. The National Neurological Conditions Surveillance System (NNCSS) was established by the CDC to track the disorder. Canada's first national dementia strategy was published in 2019. The report also helps in understanding Global Central Nervous System Therapeutics Market dynamics, structure by analyzing the market segments and project the Global Central Nervous System Therapeutics Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Central Nervous System Therapeutics Market make the report investor’s guide.

Global Central Nervous System Therapeutics Market, Key Developments:

• Innovent Biologics, Inc., a major biopharmaceutical business, reported in December 2020 that the National Medical Products Administration (NMPA) of China had approved BYVASDA, a recombinant humanised anti-VEGF monoclonal antibody medication. The central nervous system treatment solution, according to the business, is an effective therapeutic medicine that can be used to treat glioblastoma patients.

Global Central Nervous System Therapeutics Market Scope: Inquire before buying

Global Central Nervous System Therapeutics Market 2

Global Central Nervous System Therapeutics Market, By Region:

• North America • Europe • South America • MEA • APAC

Global Central Nervous System Therapeutics Market, Key players:

• Biogen • Otsuka Pharmaceutical Co., Ltd. • Eli Lilly and Company • Merck & Co. • Astra Zeneca • Shire PLC • Novartis AG • Teva Pharmaceutical Industries Ltd. • Johnson & Johnson Services, Inc. • Pfizer, Inc. • Allergan Plc. • Cipla Limited • GlaxoSmithKline plc • Lupin Limited • Lundbeck
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Central Nervous System Therapeutics Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2019 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Central Nervous System Therapeutics Market 3.4. Geographical Snapshot of the Central Nervous System Therapeutics Market, By Manufacturer share 4. Global Central Nervous System Therapeutics Market Overview, 2019-2026 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Central Nervous System Therapeutics Market 5. Supply Side and Demand Side Indicators 6. Global Central Nervous System Therapeutics Market Analysis and Forecast, 2019-2026 6.1. Global Central Nervous System Therapeutics Market Size & Y-o-Y Growth Analysis. 7. Global Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 7.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 7.1.1. Neurovascular Diseases 7.1.2. CNS Trauma 7.1.3. Mental Health 7.1.4. Neurodegenerative Diseases 7.1.5. Infectious Diseases 7.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 7.2.1. Analgesics 7.2.2. Nervous System Drugs 7.2.3. Anesthetics 7.2.4. Anti-Parkinson Drugs 7.2.5. Other Drug Classes 7.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 7.3.1. Hospital 7.3.2. Clinic 7.3.3. Homecare 7.3.4. Other 8. Global Central Nervous System Therapeutics Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2019-2026 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 9.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 9.1.1. Neurovascular Diseases 9.1.2. CNS Trauma 9.1.3. Mental Health 9.1.4. Neurodegenerative Diseases 9.1.5. Infectious Diseases 9.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 9.2.1. Analgesics 9.2.2. Nervous System Drugs 9.2.3. Anesthetics 9.2.4. Anti-Parkinson Drugs 9.2.5. Other Drug Classes 9.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 9.3.1. Hospital 9.3.2. Clinic 9.3.3. Homecare 9.3.4. Other 10. North America Central Nervous System Therapeutics Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 11.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 11.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 11.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 12. Canada Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 12.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 12.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 12.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 13. Mexico Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 13.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 13.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 13.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 14. Europe Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 14.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 14.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 14.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 15. Europe Central Nervous System Therapeutics Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 16.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 16.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 16.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 17. France Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 17.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 17.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 17.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 18. Germany Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 18.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 18.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 18.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 19. Italy Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 19.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 19.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 19.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 20. Spain Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 20.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 20.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 20.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 21. Sweden Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 21.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 21.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 21.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 22. CIS Countries Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 22.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 22.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 22.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 23. Rest of Europe Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 23.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 23.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 23.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 24. Asia Pacific Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 24.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 24.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 24.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 25. Asia Pacific Central Nervous System Therapeutics Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 26.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 26.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 26.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 27. India Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 27.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 27.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 27.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 28. Japan Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 28.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 28.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 28.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 29. South Korea Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 29.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 29.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 29.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 30. Australia Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 30.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 30.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 30.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 31. ASEAN Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 31.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 31.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 31.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 32. Rest of Asia Pacific Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 32.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 32.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 32.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 33. Middle East Africa Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 33.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 33.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 33.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 34. Middle East Africa Central Nervous System Therapeutics Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 35.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 35.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 35.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 36. GCC Countries Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 36.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 36.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 36.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 37. Egypt Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 37.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 37.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 37.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 38. Nigeria Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 38.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 38.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 38.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 39. Rest of ME&A Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 39.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 39.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 39.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 40. South America Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 40.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 40.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 40.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 41. South America Central Nervous System Therapeutics Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 42.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 42.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 42.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 43. Argentina Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 43.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 43.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 43.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 44. Rest of South America Central Nervous System Therapeutics Market Analysis and Forecasts, 2019-2026 44.1. Market Size (Value) Estimates & Forecast By Disease Type, 2019-2026 44.2. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 44.3. Market Size (Value) Estimates & Forecast By End-Users, 2019-2026 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Central Nervous System Therapeutics Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment 45.2.2. New Product Launches and Product Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. Biogen 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Product Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. Otsuka Pharmaceutical Co., Ltd. 45.3.3. Eli Lilly and Company 45.3.4. Merck & Co. 45.3.5. Astra Zeneca 45.3.6. Shire PLC 45.3.7. Novartis AG 45.3.8. Teva Pharmaceutical Industries Ltd. 45.3.9. Johnson & Johnson Services, Inc. 45.3.10. Pfizer, Inc. 45.3.11. Allergan Plc. 45.3.12. Cipla Limited 45.3.13. GlaxoSmithKline plc 45.3.14. Lupin Limited 45.3.15. Lundbeck 46. Primary Key Insights

About This Report

Report ID 108021
Category Healthcare
Published Date June 2021
Updated Date
Contact Us